A
Anjay Rastogi
Researcher at University of California, Los Angeles
Publications - 103
Citations - 4344
Anjay Rastogi is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 23, co-authored 89 publications receiving 3460 citations. Previous affiliations of Anjay Rastogi include UCLA Health & UCLA Medical Center.
Papers
More filters
Journal ArticleDOI
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis
Bevra H. Hahn,Maureen McMahon,Alan H. Wilkinson,W. Dean Wallace,David I. Daikh,John FitzGerald,George Karpouzas,Joan T. Merrill,Daniel J. Wallace,Jinoos Yazdany,Rosalind Ramsey-Goldman,Karandeep Singh,Mazdak A. Khalighi,Soo I. Choi,Maneesh Gogia,Suzanne Kafaja,Mohammad Kamgar,Christine Lau,William J. Martin,Sefali Parikh,Justin Peng,Anjay Rastogi,Weiling Chen,Jennifer M. Grossman +23 more
TL;DR: The management strategies discussed here apply to lupus nephritis in adults, particularly to those receiving care in the United States of America, and include interventions that were available in theUnited States as of April 2011.
Journal ArticleDOI
In-center hemodialysis six times per week versus three times per week.
Glenn M. Chertow,Nathan W. Levin,Gerald J. Beck,Thomas A. Depner,Paul W. Eggers,Jennifer J. Gassman,Irina Gorodetskaya,Tom Greene,Sam James,Brett Larive,Robert M. Lindsay,Ravindra L. Mehta,Brent W. Miller,Daniel B. Ornt,Sanjay Rajagopalan,Anjay Rastogi,Michael V. Rocco,Brigitte Schiller,Olga Sergeyeva,Gerald Schulman,George Ting,Mark Unruh,Robert A. Star,Alan S. Kliger +23 more
TL;DR: Frequent hemodialysis, as compared with conventional hemodIALysis, was associated with favorable results with respect to the composite outcomes of death or change in left ventricular mass and death orchange in a physical-health composite score but prompted more frequent interventions related to vascular access.
Journal ArticleDOI
Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
Louis Holdstock,Amy M Meadowcroft,Rayma Maier,Brendan M. Johnson,Delyth Jones,Anjay Rastogi,Steven Zeig,John J. Lepore,Alexander R. Cobitz +8 more
TL;DR: GSK1278863 may prove an effective alternative for managing anemia of CKD and was generally safe and well tolerated at the doses and duration studied, with clinically significant elevations in plasma vascular endothelial growth factor concentrations.
Journal ArticleDOI
A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients
Jürgen Floege,Adrian Covic,Markus Ketteler,Anjay Rastogi,Edward M.F. Chong,Sylvain Gaillard,Laura J. Lisk,Stuart M. Sprague +7 more
TL;DR: PA21 was effective in lowering serum phosphorus in dialysis patients, with similar efficacy to sevelamer carbonate, a lower pill burden, and better adherence, and the PA21 maintenance dose was superior to the low dose in maintaining serum phosphorus control.
Journal ArticleDOI
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Fouad T. Chebib,Ronald D. Perrone,Arlene B. Chapman,Neera K. Dahl,Peter C. Harris,Michal Mrug,Reem A. Mustafa,Anjay Rastogi,Terry Watnick,Alan S.L. Yu,Vicente E. Torres +10 more
TL;DR: Practical guidance is provided and steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively are discussed.